Adaptimmune

Helen Tayton-Martin, Ph.D., Chief Operating Officer
Private Company
Headquarters: Oxford, U.K.
Established in July 2008 with a research base in Oxford, U.K. and a clinical base in Philadelphia, U.S., Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune undertakes all of its own research and development using proprietary T cell receptor engineering technology co-developed with its sister company Immunocore Ltd. (formerly Avidex/MediGene) and exclusively licensed for T cell therapy. Backed by private investors, Adaptimmune is now in the clinic in the U.S., in multiple cancer indications with its engineered TCR to the NY-ESO-1/LAGE-1 cancer testis antigen.